Findings from interim data of European study revealed a reduction in mortality from prostate cancer in men who were screened for the disease. When compared to European study, US study showed no mortality benefit from prostate cancer screening. European Randomized Trial of Screening for Prostate Cancer (ERSPC) showed 20% reduction in the rate of death from prostate cancer by screening prostate-specific antigen (PSA). An absolute reduction of approximately 7 prostate-cancer-related deaths per 10,000 men screened was observed. Fritz Schröder, MD, from the Erasmus Medical Center, in Rotterdam, the Netherlands reported that clinicians may tell patients that screening for prostate cancer will decrease their probability of dying from the disease. Before the study, clinicians would have to admit to their patients that they did not know whether prostate cancer screening decreases the rate of death from prostate cancer. Dr. Schröder noted that for some patients, a diagnosis of prostate cancer can lead to unnecessary treatment, which can be associated with major adverse effects. Some cases of prostate cancer are very slow growing and may not call for treatment, but instead can be followed with active surveillance or watchful waiting.